| KALVISTA PHARMACEUTICALS |
| USA |
| Gesundheit |
| US4834971032 / A2DG49 |
| 4XC1 (Frankfurt) / KALV (NASDAQ) |
| FRA:4XC1, ETR:4XC1, 4XC1:GR, NASDAQ:KALV |
| - |
| https://www.kalvista.com/ |
|
KalVista Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet medical needs, particularly hereditary angioedema (HAE..
>Volltext.. |
| 877.29 Mio. EUR |
| 863.67 Mio. EUR |
| 1.24 Mio. EUR |
| -174.84 Mio. EUR |
| -175.95 Mio. EUR |
| -3.46 EUR |
| 246.21 Mio. EUR |
| 198.68 Mio. EUR |
| -144.84 Mio. EUR |
| 5.23 |
| - |
| -35.86% |
| - |
| - |
| - |
| KALVISTA |
| 04.04.26 |
|
||||
|
||||
|
||||
|